⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Cellestia Biotech AG and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Cellestia Biotech AG
↗Basel, Switzerland
Cellestia Biotech is a Swiss clinical-stage biopharmaceutical company focused on developing first-in-class targeted therapeutics to address unmet medical needs in oncology and immunology. The company specializes in modulating pathogenic gene expression by selectively inhibiting transcription factors, specifically targeting the Notch signaling pathway.
Founded in 2014 as a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), the company has built a robust R&D pipeline. Its lead candidate, CB-103, is an oral small-molecule pan-NOTCH inhibitor currently in clinical development for various cancers, including leukemia, lymphoma, and solid tumors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2014
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$30M+
Investors:TVM Capital Life Science, SNGLR Capital AG
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Anciata Therapeutics, Inc. (Spin-off)
Key Partnerships:TVM Capital Life Science (Joint investment in Anciata Therapeutics)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, BeiGene, Sana Biotechnology
LEADERSHIP
Key Executives:
Michael Bauer - CEO
Rajwinder Lehal - CSO
Scientific Founders:Rajwinder Lehal
Board Members:Rajwinder Lehal
LINKS
Website:cellestia.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cellestia Biotech AG. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.